2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2710

Deficiency Of The Protein Kinase Ataxia Telangiectasia Mutated Accelerates T Cell Aging In Rheumatoid Arthritis
Abstract Number: 1586

Defining Hand Arthritis In Systemic Lupus Erythematosus, From An Ultrasound, Magnetic Resonance Imaging and Antibody Status Perspective
Abstract Number: 2086

Defining The Prevalence and Associated Risk Factors For Calcinosis In Adult Dermatomyositis Patients
Abstract Number: 2203

DEK’s Autoantigenicity In Juvenile Idiopathic Arthritis Resides In Its C-Terminal 25 Amino Acids
Abstract Number: 186

Delay In Consultation and Starting Disease Modifying Anti-Rheumatic Drugs In Patients With Rheumatoid Arthritis In Argentina. How Early Arthritis Clinics Impact On Health Barriers?
Abstract Number: 1296

Deletion Of RBP-J In a Murine Model Of Inflammatory Arthritis Reveals Pro-Inflammatory Cytokine Expression and Immunophenotypic Differences
Abstract Number: 2533

Delta Neutrophil Index As a Marker For Differential Diagnosis Between Flare and Infection In Febrile Systemic Lupus Erythematosus Patients
Abstract Number: 2905

Demethylation of ITGAL (CD11a) regulatory sequences in CD4+T lymphocytes of Systemic Sclerosis
Abstract Number: 1237

Denosumab Leads To Significantly Greater Increases In Bone Mineral Density Than Ibandronate and Risedronate In Postmenopausal Women At High Risk For Fracture Who Were Previously Treated With An Oral Bisphosphonate
Abstract Number: 556

Depletion Of The Gut Microbiota Prevents β₂-Glycoprotein I Antibody Production and Mortality In a Model Of Antiphospholipid Syndrome
Abstract Number: 1066

Depression Screening In Patients With Systemic Lupus Erythematosus From The Southeastern United States: Missing Opportunities For Early Diagnosis and Treatment
Abstract Number: 1256

Depression, Anxiety and Suicidal Thoughts In a Cohort Of Pediatric Lupus and Mixed Connective Tissue Disease Patients
Abstract Number: 2035

Description Of 142 Cases Of Relapsing Polychondritis Followed In a Single Center Since 2000
Abstract Number: 691

Descriptive Review Of Morphea Subjects From a Single Cohort Center
Abstract Number: 1567

Desensitization To Trimethoprim/Sulfamethoxazole In Systemic Lupus Erythematosus Patients : A Retrospective Cohort Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].